CN111249475A - 一种药物和基因双重运载系统、其制备方法及应用 - Google Patents
一种药物和基因双重运载系统、其制备方法及应用 Download PDFInfo
- Publication number
- CN111249475A CN111249475A CN202010114511.1A CN202010114511A CN111249475A CN 111249475 A CN111249475 A CN 111249475A CN 202010114511 A CN202010114511 A CN 202010114511A CN 111249475 A CN111249475 A CN 111249475A
- Authority
- CN
- China
- Prior art keywords
- carrier
- solution
- avidin
- drug
- delivery system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 229940079593 drug Drugs 0.000 title claims abstract description 52
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 31
- 230000009977 dual effect Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims abstract description 60
- 108090001008 Avidin Proteins 0.000 claims abstract description 45
- 229920001503 Glucan Polymers 0.000 claims abstract description 43
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 37
- -1 polytrimethylene carbonate Polymers 0.000 claims abstract description 33
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 16
- 238000006243 chemical reaction Methods 0.000 claims abstract description 14
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 12
- 239000011258 core-shell material Substances 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 46
- 239000007864 aqueous solution Substances 0.000 claims description 25
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 24
- 229920002307 Dextran Polymers 0.000 claims description 21
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 21
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 19
- 239000002245 particle Substances 0.000 claims description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 17
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 15
- 239000000839 emulsion Substances 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000012279 sodium borohydride Substances 0.000 claims description 9
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 9
- 150000005846 sugar alcohols Polymers 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 7
- 239000006184 cosolvent Substances 0.000 claims description 7
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 238000006722 reduction reaction Methods 0.000 claims description 5
- 210000003022 colostrum Anatomy 0.000 claims description 4
- 235000021277 colostrum Nutrition 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 2
- 238000012377 drug delivery Methods 0.000 claims 2
- 238000001476 gene delivery Methods 0.000 claims 2
- 239000002539 nanocarrier Substances 0.000 abstract description 14
- 238000011282 treatment Methods 0.000 abstract description 10
- 229960002685 biotin Drugs 0.000 abstract description 7
- 239000011616 biotin Substances 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 239000002502 liposome Substances 0.000 abstract description 5
- 125000002091 cationic group Chemical group 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract description 3
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 231100000086 high toxicity Toxicity 0.000 abstract description 3
- 239000004055 small Interfering RNA Substances 0.000 description 22
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 20
- 239000002105 nanoparticle Substances 0.000 description 15
- 238000001415 gene therapy Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 125000003172 aldehyde group Chemical group 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 238000005034 decoration Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010114511.1A CN111249475B (zh) | 2020-02-24 | 2020-02-24 | 一种药物和基因双重运载系统、其制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010114511.1A CN111249475B (zh) | 2020-02-24 | 2020-02-24 | 一种药物和基因双重运载系统、其制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111249475A true CN111249475A (zh) | 2020-06-09 |
CN111249475B CN111249475B (zh) | 2024-05-10 |
Family
ID=70941709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010114511.1A Active CN111249475B (zh) | 2020-02-24 | 2020-02-24 | 一种药物和基因双重运载系统、其制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111249475B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1561969A (zh) * | 2004-03-17 | 2005-01-12 | 天津大学 | 同载基因和药物的超微载体粒子及其制备方法 |
CN1683016A (zh) * | 2005-03-16 | 2005-10-19 | 天津大学 | 用于胶质瘤靶向化疗的表面含转铁蛋白载药微粒制备方法 |
CN1768860A (zh) * | 2005-10-24 | 2006-05-10 | 天津大学 | 基于酰肼基的微粒表面多重生物功能因子组装方法 |
CN1768859A (zh) * | 2005-10-24 | 2006-05-10 | 天津大学 | 基于醛基的微粒表面多重生物功能因子组装方法 |
CN102657873A (zh) * | 2012-05-21 | 2012-09-12 | 苏州大学 | 一种双亲性聚合物构成的囊泡及其应用 |
CN102836147A (zh) * | 2011-06-25 | 2012-12-26 | 复旦大学 | 一种包载紫杉醇的生物可降解纳米复合物及其制备方法 |
US20150209288A1 (en) * | 2012-02-21 | 2015-07-30 | Amrita Vishwa Vidyapeetham | Core-shell particle formulation for delivering multiple therapeutic agents |
-
2020
- 2020-02-24 CN CN202010114511.1A patent/CN111249475B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1561969A (zh) * | 2004-03-17 | 2005-01-12 | 天津大学 | 同载基因和药物的超微载体粒子及其制备方法 |
CN1683016A (zh) * | 2005-03-16 | 2005-10-19 | 天津大学 | 用于胶质瘤靶向化疗的表面含转铁蛋白载药微粒制备方法 |
CN1768860A (zh) * | 2005-10-24 | 2006-05-10 | 天津大学 | 基于酰肼基的微粒表面多重生物功能因子组装方法 |
CN1768859A (zh) * | 2005-10-24 | 2006-05-10 | 天津大学 | 基于醛基的微粒表面多重生物功能因子组装方法 |
CN102836147A (zh) * | 2011-06-25 | 2012-12-26 | 复旦大学 | 一种包载紫杉醇的生物可降解纳米复合物及其制备方法 |
US20150209288A1 (en) * | 2012-02-21 | 2015-07-30 | Amrita Vishwa Vidyapeetham | Core-shell particle formulation for delivering multiple therapeutic agents |
CN102657873A (zh) * | 2012-05-21 | 2012-09-12 | 苏州大学 | 一种双亲性聚合物构成的囊泡及其应用 |
Non-Patent Citations (1)
Title |
---|
刘海蓉;张清卿;周征;胡薏冰;张水寒;戴瑶;李永生;: "PHBV/葡聚糖纳米药物载体的制备及表征", 湖南大学学报(自然科学版), no. 06, 25 June 2018 (2018-06-25), pages 114 - 119 * |
Also Published As
Publication number | Publication date |
---|---|
CN111249475B (zh) | 2024-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xue et al. | DNA tetrahedron-based nanogels for siRNA delivery and gene silencing | |
Bai et al. | Non-viral nanocarriers for intracellular delivery of microRNA therapeutics | |
Lee et al. | MicroRNA delivery through nanoparticles | |
Fu et al. | Recent progress in microRNA-based delivery systems for the treatment of human disease | |
KR101460204B1 (ko) | 친수성 핵산 유전자를 유기용매에 가용화시키고, 이를 소수성 미립자에 봉입한 제어방출형 유전자 전달용 복합체와 이의 제조방법 | |
CN104258416B (zh) | 基于寡聚核苷酸共递送药物和基因的纳米载体及制备方法 | |
De Martimprey et al. | New core-shell nanoparticules for the intravenous delivery of siRNA to experimental thyroid papillary carcinoma | |
Zokaei et al. | Therapeutic potential of DNAzyme loaded on chitosan/cyclodextrin nanoparticle to recovery of chemosensitivity in the MCF-7 cell line | |
David-Naim et al. | Polymeric nanoparticles of siRNA prepared by a double-emulsion solvent-diffusion technique: Physicochemical properties, toxicity, biodistribution and efficacy in a mammary carcinoma mice model | |
JP5804453B2 (ja) | 結晶性ポリオール微粒子及びその調製方法 | |
Wang et al. | microRNAs as therapeutic targets in intestinal diseases | |
Luo et al. | RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles | |
CN113975398B (zh) | 一种用于治疗肝纤维化的药物递送载体组合物及其制备方法 | |
Parnian et al. | Overcoming the non-kinetic activity of EGFR1 using multi-functionalized mesoporous silica nanocarrier for in vitro delivery of siRNA | |
Zhu et al. | Nucleic acid-based artificial nanocarriers for gene therapy | |
Myoung et al. | Strategies for safe and targeted delivery of microRNA therapeutics | |
Chen et al. | The Hydrophobicity of AIE Dye Facilitates DNA Condensation for Carrier‐Free Gene Therapy | |
Maksimenko et al. | Oligonucleotides targeted against a junction oncogene are made efficient by nanotechnologies | |
Zou et al. | Nanocarrier‐delivered small interfering RNA for chemoresistant ovarian cancer therapy | |
CN111249475A (zh) | 一种药物和基因双重运载系统、其制备方法及应用 | |
Nasiri et al. | Improving DNA nanostructure stability: A review of the biomedical applications and approaches | |
Moniri Javadhesari et al. | A review on the application of nanoparticles for targeted gene delivery | |
WO2012068870A1 (zh) | 三元复合物和含有三元复合物的液体及制备方法与应用 | |
CN107349432A (zh) | 一种负载索拉菲尼/siRNA的介孔二氧化硅‑乳糖醛酸靶向纳米颗粒 | |
Stoleru et al. | Nucleic acids–based bionanomaterials for drug and gene therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240415 Address after: No. 188, Section 1, Furong South Road, Tianxin District, Changsha, Hunan 410000 Applicant after: AIER EYE HOSPITAL GROUP Co.,Ltd. Country or region after: China Applicant after: SHENZHEN RESEARCH INSTITUTE OF HUNAN University Applicant after: THE SECOND XIANGYA HOSPITAL OF CENTRAL SOUTH University Address before: 410000 First Floor of the Provincial Scientific Research Achievement Conversion Center of Longping High-tech Park, No. 99 Changchong Road, Furong District, Changsha City, Hunan Province Applicant before: AIER EYE HOSPITAL GROUP Co.,Ltd. Country or region before: China |
|
GR01 | Patent grant | ||
GR01 | Patent grant |